Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Debt / DBCV 0.250% 2/0
-
Market price (% of par)
-
98.88%
-
Total 13F principal
-
$22,297,898
-
Principal change
-
-$15,560,102
-
Total reported market value
-
$21,796,955
-
Number of holders
-
10
-
Value change
-
-$15,388,000
-
Number of buys
-
1
-
Number of sells
-
2
Institutional Holders of TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 as of Q1 2022
As of 31 Mar 2022,
TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 was held by
10 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$22,297,898
in principal (par value) of the bond.
The largest 10 bondholders included
INCOME RESEARCH & MANAGEMENT, WELLINGTON MANAGEMENT GROUP LLP, Russell Investments Group, Ltd., HighTower Advisors, LLC, COMMONWEALTH EQUITY SERVICES, LLC, Creative Planning, MORGAN STANLEY, WELLS FARGO & COMPANY/MN, BANK OF AMERICA CORP /DE/, and American Portfolios Advisors.
This page lists
10
institutional bondholders reporting positions
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.